Calapai Marco, Esposito Emanuela, Puzzo Luisa, Vecchio Daniele Alfio, Blandino Rosario, Bova Giuseppe, Quattrone Domenico, Mannucci Carmen, Ammendolia Ilaria, Mondello Cristina, Gangemi Sebastiano, Calapai Gioacchino, Cardia Luigi
Breast Unit, San Vincenzo Hospital, Azienda Sanitaria Provinciale Messina, 98039 Messina, Italy.
Genetics and Pharmacogenetics Unit, Policlinico Universitario "G. Martino", University of Messina, 98125 Messina, Italy.
Life (Basel). 2021 Sep 29;11(10):1026. doi: 10.3390/life11101026.
After breast surgery, women frequently develop chronic post-mastectomy pain (PMP). PMP refers to the occurrence of pain in and around the area of the mastectomy lasting beyond three months after surgery. The nature of factors leading to PMP is not well known. When PMP is refractory to analgesic treatment, it negatively impacts the lives of patients, increasing emotional stress and disability. For this reason, optimizing the quality of life of patients treated for this pathology has gained more importance. On the basis of the findings and opinions above, we present an overview of risk factors and predictors to be used as potential biomarkers in the personalized management of individual PMP. For this overview, we discuss scientific articles published in peer-reviewed journals written in the English language describing risk factors, predictors, and potential biomarkers associated with chronic pain after breast surgery. Our overview confirms that the identification of women at risk for PMP is fundamental to setting up the best treatment to prevent this outcome. Clinical practice can be planned through the interpretation of genotyping data, choosing drugs, and tailoring doses for each patient with the aim to provide safer and more effective individual analgesic treatment.
乳房手术后,女性经常会出现慢性乳房切除术后疼痛(PMP)。PMP是指乳房切除术区域及其周围出现的疼痛,术后持续超过三个月。导致PMP的因素性质尚不清楚。当PMP对镇痛治疗无效时,会对患者的生活产生负面影响,增加情绪压力和残疾程度。因此,优化患有这种病症的患者的生活质量变得更加重要。基于上述发现和观点,我们概述了风险因素和预测指标,这些可作为个体PMP个性化管理中的潜在生物标志物。对于本概述,我们讨论了发表在同行评审英文期刊上的科学文章,这些文章描述了与乳房手术后慢性疼痛相关的风险因素、预测指标和潜在生物标志物。我们的概述证实,识别有PMP风险的女性对于制定最佳治疗方案以预防这种结果至关重要。临床实践可以通过解读基因分型数据、为每位患者选择药物和调整剂量来进行规划,目的是提供更安全、更有效的个体化镇痛治疗。